JP7425452B2 - クロストリジウム・ディフィシル菌に結合する抗体 - Google Patents

クロストリジウム・ディフィシル菌に結合する抗体 Download PDF

Info

Publication number
JP7425452B2
JP7425452B2 JP2022566303A JP2022566303A JP7425452B2 JP 7425452 B2 JP7425452 B2 JP 7425452B2 JP 2022566303 A JP2022566303 A JP 2022566303A JP 2022566303 A JP2022566303 A JP 2022566303A JP 7425452 B2 JP7425452 B2 JP 7425452B2
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
heavy chain
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022566303A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023277142A1 (https=
Inventor
礼子 新藏
智行 森
竜太郎 玉野
直 堂前
敏雄 箱嶋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nara Institute of Science and Technology NUC
University of Tokyo NUC
Original Assignee
Nara Institute of Science and Technology NUC
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nara Institute of Science and Technology NUC, University of Tokyo NUC filed Critical Nara Institute of Science and Technology NUC
Publication of JPWO2023277142A1 publication Critical patent/JPWO2023277142A1/ja
Priority to JP2023107219A priority Critical patent/JP7405386B2/ja
Priority to JP2024002756A priority patent/JP2024041901A/ja
Application granted granted Critical
Publication of JP7425452B2 publication Critical patent/JP7425452B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022566303A 2021-07-01 2022-06-30 クロストリジウム・ディフィシル菌に結合する抗体 Active JP7425452B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023107219A JP7405386B2 (ja) 2021-07-01 2023-06-29 クロストリジウム・ディフィシル菌に結合する抗体
JP2024002756A JP2024041901A (ja) 2021-07-01 2024-01-11 クロストリジウム・ディフィシル菌に結合する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021110421 2021-07-01
JP2021110421 2021-07-01
PCT/JP2022/026277 WO2023277142A1 (ja) 2021-07-01 2022-06-30 クロストリジウム・ディフィシル菌に結合する抗体

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023107219A Division JP7405386B2 (ja) 2021-07-01 2023-06-29 クロストリジウム・ディフィシル菌に結合する抗体
JP2024002756A Division JP2024041901A (ja) 2021-07-01 2024-01-11 クロストリジウム・ディフィシル菌に結合する抗体

Publications (2)

Publication Number Publication Date
JPWO2023277142A1 JPWO2023277142A1 (https=) 2023-01-05
JP7425452B2 true JP7425452B2 (ja) 2024-01-31

Family

ID=84692781

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022566303A Active JP7425452B2 (ja) 2021-07-01 2022-06-30 クロストリジウム・ディフィシル菌に結合する抗体
JP2023107219A Active JP7405386B2 (ja) 2021-07-01 2023-06-29 クロストリジウム・ディフィシル菌に結合する抗体
JP2024002756A Pending JP2024041901A (ja) 2021-07-01 2024-01-11 クロストリジウム・ディフィシル菌に結合する抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023107219A Active JP7405386B2 (ja) 2021-07-01 2023-06-29 クロストリジウム・ディフィシル菌に結合する抗体
JP2024002756A Pending JP2024041901A (ja) 2021-07-01 2024-01-11 クロストリジウム・ディフィシル菌に結合する抗体

Country Status (9)

Country Link
US (1) US20250188157A1 (https=)
EP (1) EP4365293A4 (https=)
JP (3) JP7425452B2 (https=)
KR (1) KR20240026999A (https=)
CN (1) CN117716035A (https=)
AU (1) AU2022305377A1 (https=)
CA (1) CA3224497A1 (https=)
TW (1) TW202317611A (https=)
WO (1) WO2023277142A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202440928A (zh) 2023-03-03 2024-10-16 國立大學法人東京大學 免疫球蛋白
CN121127591A (zh) 2023-05-12 2025-12-12 国立大学法人东京大学 与艰难梭菌结合的抗体
WO2025134928A1 (ja) * 2023-12-21 2025-06-26 国立大学法人 東京大学 結腸直腸がんを治療するための組成物
WO2025220732A1 (ja) * 2024-04-17 2025-10-23 国立研究開発法人国立循環器病研究センター 肺高血圧症の予防又は治療薬
WO2025225737A1 (ja) * 2024-04-26 2025-10-30 国立大学法人 東京大学 微生物と抗体の組み合わせおよび使用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003104A1 (en) 2001-07-02 2003-01-02 John Mottola Method for removal of pathogens from a localized environment
WO2014142084A1 (ja) 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2017001987A (ja) 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030003104A1 (en) 2001-07-02 2003-01-02 John Mottola Method for removal of pathogens from a localized environment
WO2014142084A1 (ja) 2013-03-11 2014-09-18 学校法人関西文理総合学園 モノクローナルＩｇＡ抗体の製造方法
JP2017001987A (ja) 2015-06-11 2017-01-05 学校法人関西文理総合学園 ポリペプチド

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
International Immunology，Vol.33, No.12，p.787-790
Nature Microbiology，2016年，Vol.1，Article No.16103
The Japanese Journal of Antibiotics，2017年，Vol.70, No.1，p.1-13
日本臨床免疫学会会誌，2017年，Vol.40, No.6，p.408-415

Also Published As

Publication number Publication date
KR20240026999A (ko) 2024-02-29
AU2022305377A1 (en) 2024-02-15
JP2023123746A (ja) 2023-09-05
EP4365293A4 (en) 2026-03-11
CA3224497A1 (en) 2023-01-05
JPWO2023277142A1 (https=) 2023-01-05
TW202317611A (zh) 2023-05-01
US20250188157A1 (en) 2025-06-12
JP2024041901A (ja) 2024-03-27
JP7405386B2 (ja) 2023-12-26
EP4365293A1 (en) 2024-05-08
CN117716035A (zh) 2024-03-15
WO2023277142A1 (ja) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7405386B2 (ja) クロストリジウム・ディフィシル菌に結合する抗体
JP7430946B2 (ja) クロストリジウム・ディフィシル菌の増殖を抑制するためのモノクローナル抗体含有組成物
US9765151B2 (en) Method for producing monoclonal IgA antibody
KR20120128687A (ko) 녹농균의 혈청형 ｇ 지질다당류에 대한 항체
US10316079B2 (en) Monoclonal antibody against muramyl peptides
WO2023219175A1 (ja) 炎症性腸疾患（ｉｂｄ）を治療または診断する方法および組成物
EP4410309A1 (en) Composition containing monoclonal antibody
WO2024237217A1 (ja) クロストリジオイデス・ディフィシル菌に結合する抗体
TW202608478A (zh) 微生物與抗體之組合及用途
KR20250158030A (ko) 면역 글로불린
WO2025225737A1 (ja) 微生物と抗体の組み合わせおよび使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221028

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221028

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20221115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240111

R150 Certificate of patent or registration of utility model

Ref document number: 7425452

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150